Royal Marsden NHS Foundation Trust, London, UK.
Radboud University Medical Centre, Nijmegen, the Netherlands.
Eur J Cancer. 2019 Nov;122:1-8. doi: 10.1016/j.ejca.2019.08.020. Epub 2019 Oct 5.
Tumour deposits (TDs) are a poor prognostic marker in colorectal cancer, but their significance after neoadjuvant chemoradiotherapy is less certain because this group of patients is excluded in most studies. Post-treatment TD might even be a sign of tumour response. No previous reviews have assessed outcomes in this group.
A systematic review and meta-analysis was undertaken according to Preferred Reporting for Systematic Reviews and Meta-Analyses guidelines to determine the relevance of post-treatment TD. Inclusion criteria were studies assessing TD in patients who had undergone pre-operative treatment with radiotherapy and/or chemotherapy and reporting prevalence and survival outcomes. Studies that did not include histological review of cases were excluded.
Eight studies and 1283 patients were included in the review. Prevalence of TDs varied from 11.8% to 44.2% (mean 23.7%), similar to untreated patients. The presence of TDs after chemoradiotherapy was associated with invasion depth, lymph node involvement, perineural invasion and synchronous metastases. The pooled hazard ratio for 5-year adverse disease-free survival was 2.3 (95% confidence interval [CI]: 1.8-2.9), and that for overall survival was 2.5 (95% CI: 1.9-3.3). One study showed a survival benefit with adjuvant therapy in the TD-positive group.
In analogy with untreated patients, the presence of TDs in patients with rectal cancer after neoadjuvant treatment is associated with advanced disease and a poor outcome.
肿瘤沉积(TDs)是结直肠癌的一个不良预后标志物,但在新辅助放化疗后其意义尚不确定,因为这组患者在大多数研究中被排除在外。治疗后 TD 甚至可能是肿瘤反应的标志。以前没有综述评估过这组患者的结局。
根据系统评价和荟萃分析的首选报告指南,进行了系统评价和荟萃分析,以确定治疗后 TD 的相关性。纳入标准是评估接受过放疗和/或化疗术前治疗的患者中 TD 的研究,并报告患病率和生存结局。未包括对病例进行组织学检查的研究被排除在外。
综述纳入了 8 项研究和 1283 名患者。TDs 的患病率从 11.8%到 44.2%(平均 23.7%)不等,与未经治疗的患者相似。放化疗后存在 TD 与浸润深度、淋巴结受累、神经周围侵犯和同步转移有关。5 年不良无病生存率的合并危险比为 2.3(95%置信区间 [CI]:1.8-2.9),总生存率的合并危险比为 2.5(95% CI:1.9-3.3)。一项研究表明,在 TD 阳性组中,辅助治疗有生存获益。
与未经治疗的患者类似,新辅助治疗后直肠癌症患者存在 TD 与疾病进展和预后不良有关。